ST. LOUIS--(BUSINESS WIRE)--Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm in the United States. This recognition places Cornfed Farms as one of 16 farms around the globe, highlighted by Bayer as committed to advancing regenerative agriculture practices that ensure economic success while promoting environmental stewardship. Bayer ForwardFarming is. ...

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 每日经济新闻 （责任编辑：王治强 HF013） 每经AI快讯，10月7日，拜耳集团股价下跌2%。 ...

Core Insights - Bayer is participating in the 8th China International Import Expo (CIIE) with a focus on its mission of "sharing health and eliminating hunger," showcasing its commitment to the Chinese market and its confidence in leveraging local development opportunities [1][2] Group 1: Participation and Commitment - Bayer will have a total exhibition area of 800 square meters across two halls, continuing its presence at the CIIE for the eighth consecutive year, highlighting its long-term commitment to the Chinese market [1] - The company aims to leverage the CIIE as a strategic platform to connect with global innovations and observe China's market opportunities [2] Group 2: Product Innovations - Bayer will showcase approximately 26 highlight exhibits, including 5 global debuts, 8 China debuts, and 13 CIIE debuts, emphasizing its century-long innovation legacy [2] - In the prescription drug sector, Bayer will present innovations in oncology, cardiovascular, ophthalmology, and women's health, including the domestic debut of Eylea® 8mg, which offers significant benefits for patients with age-related macular degeneration [3] - The imaging diagnostics segment will feature locally produced products, including the MEDRAD® Stellant D-CE high-pressure injection system, marking a key milestone in local production [4] - In the consumer health sector, Bayer will introduce new products addressing allergies, digestive health, nutrition, and skin care, including the new member of the Claritin® family, which is recommended for children [5] Group 3: Agricultural Innovations - Bayer will integrate global wisdom with local innovation in agriculture, presenting 7 China debuts and 8 CIIE debuts, including new products in crop health and seed varieties tailored to local farmer needs [6] - The company is committed to sustainable agricultural development in China, showcasing its third regenerative agriculture demonstration farm and various local partnerships aimed at enhancing productivity for smallholder farmers [10] Group 4: Collaborative Efforts - Bayer emphasizes the importance of local collaboration for effective innovation, having established partnerships with startups and academic institutions to drive advancements in healthcare and agricultural technology [7][9] - The company is launching the Bayer Health Consumer Innovation Cooperation Center (CCIP) in 2024 to foster a collaborative ecosystem among top universities and research institutions in China [9] Group 5: Future Outlook - Bayer's participation in the CIIE is seen as a significant opportunity to align with China's development trajectory, aiming to create a better life for the Chinese populace through innovation and collaboration [10]

数据显示，美国是德国制药业最重要的出口市场。2024年，德国向美出口药品总额达270亿欧元，占行业出口总量 的约四分之一。德国制药业目前在美雇用大量员工并拥有生产设施。 德国药剂师协会联合会也对关税可能带来的后果表示担忧。协会主席普赖斯指出，如果美国市场受阻，可能导致 德国本土药品生产因经济性受损而被限制，进而影响药品供应稳定性。业内人士同时提醒，德国自美国进口的成 品药和部分关键原材料占比较高，若贸易摩擦升级，价格上涨或供给短缺将直接冲击生产环节。 德国拜耳集团首席执行官安德森警告称，长期维持高关税将削弱制药企业的运营和研发能力，危及行业的创新活 力与竞争力。 德国业界呼吁，欧洲应加快寻求应对方案，更好发挥欧盟内部市场的潜力，以增强自身抗风险能力，避免在国际 经贸摩擦中沦为被动。（总台记者 阮佳闻） 针对美国宣布拟自10月1日起对药品进口征收100%关税的计划，德国制药界和药剂师组织表达强烈担忧，认为此 举将对国际供应链、生产与投资造成严重冲击，并可能危及患者用药保障。 德国研究型制药企业协会当地时间26日指出，这一决定与此前美欧之间规定关税上限为15%的贸易安排相违背， 若付诸实施，将成为德国和欧洲制药业 ...

Here are the stocks with buy rank and strong value characteristics for investors to consider today, September 26th:  Bayer (BAYRY) : This global company with core competencies in the areas of health care and nutrition, carries a Zacks Rank #1 (Strong Buy), and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.8% over the last 60 days.Bayer's has a price-to-earnings ratio (P/E) of 5.97 compared with 13.50 for the industry. The company possesses a Value Score of A.Cars.com ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bayer Canada is pleased to announce a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL® 30 mg tablets1 in Canada. This strategic collaboration took effect on September 3, 2025. "We are excited to partner with Mint Pharmaceuticals Inc., a company known for its commitment to quality and customer service,†said Viktoria Friedrich, Country President and General Manager at Bayer Inc., Pharmaceutical Division. "This partnership w. ...

来源：ESG评级中心 点击查看更多企业ESG评级。 据新浪财经ESG评级中心，2025年09月22日，拜耳（BAYRY.US）MSCI（明晟）ESG评级由A调升至 AA。 ...

Core Insights - Bayer's CEO Bill Anderson highlighted the company's "remarkable progress" in addressing longstanding challenges, particularly a weak drug development pipeline [1] Group 1 - The company is focusing on overcoming challenges related to its drug development pipeline [1] - Internal management changes have been implemented to facilitate progress [1]

Bayer has started the third phase of human testing of an experimental stem cell therapy for Parkinson's disease, with future results potentially underpinning a request for regulatory approval, the com... ...

Core Insights - Bayer has made significant progress in developing two potential therapies for Parkinson's disease (PD) [1] Group 1: Clinical Trials - The first participant has been randomized in the pivotal Phase III clinical trial, exPDite-2, for bemdaneprocel, which is an investigational cell therapy for PD [1] - The first European participants have been randomized in the Phase II clinical trial, REGENERATE-PD, for AB-1005, an investigational gene therapy [1] - Both therapies are aimed at treating moderate-stage Parkinson's disease [1]